drugset / Trial / NCT02466984

Subcutaneous Route and Pharmacology of Metoclopramide

NCT02466984

Phase 3 Completed 5 enrolled University Hospital, Bordeaux
RandomizedCrossoverOpen-labelTreatment

Summary

Subcutaneous (SC) route has become a standard of care of many drugs administration in palliative medicine. A preliminary study showed that, although it was widely adopted among palliative care practitioners for routinely prescribed medications, standards of proof are still lacking for many molecules. Among them, metoclopramide is a largely employed drug for nausea and vomiting treatment, particularly in palliative care and oncology. Therefore, the investigator aim to study absorption and efficacy of subcutaneous administration of metoclopramide.

Timeline

Start
2016-07
Primary completion
2018-02-08
Completion
2019-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Metoclopramide Small molecule 10 mg Subcutaneous
Subject Metoclopramide Small molecule 20 mg Subcutaneous
Subject Metoclopramide Small molecule 30 mg Subcutaneous

Indications

No indication recorded.